Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Med Oncol
Hlavní autoři: Lee, Min-Sang, Cho, Hee Jin, Hong, Jung Yong, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Cho, Yong Beom, Kim, Seung Tae
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7649869/
https://ncbi.nlm.nih.gov/pubmed/33224274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920965842
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky